MedTrace Logo

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients

NCT01066065 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2010-06-25

No results posted yet for this study

Summary

The advent of new antiretroviral drugs improved the management of HIV naive patients in terms of efficacy. However, the long term metabolic profile of this drugs has not yet been compared and associations between new antiretrovirals and cardiovascular events remains controversial.

Moreover, the better tolerability and easy dosage of this new drugs might hypothetically influence adherence and QOL of HIV patients.

Conditions

Sponsors & Collaborators

  • Hospital Carlos III, Madrid

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01066065 on ClinicalTrials.gov